Lawsuit Pending for Investors in Agenus Inc. (NASDAQ: AGEN) Shares – Contact Shareholders Foundation for Options

Investors in Agenus Inc. (NASDAQ: AGEN) are facing a potential lawsuit over alleged securities laws violations. The lawsuit stems from concerns raised about the effectiveness of the company’s immunotherapy combination for the treatment of colorectal cancer.

According to a press release from Agenus Inc. on July 18, 2024, the FDA advised against submission of the results of an “end-of-Phase 2 (EOP2) meeting” for the company’s immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), citing concerns about the translation of objective response rates to survival benefit.

Following this announcement, an investor in NASDAQ: AGEN shares filed a lawsuit on September 6, 2024, alleging that the company made false and misleading statements about the effectiveness of the combination therapy. The plaintiff claims that the clinical results and regulatory prospects were overstated, leading to misleading public statements by the company.

Investors who purchased shares of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023, and July 17, 2024, are urged to contact the Shareholders Foundation, Inc. for more information on their options. The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and settlement claim filing service that provides information on shareholder issues and securities class actions.

For more information, investors can contact Michael Daniels at mail@shareholdersfoundation.com or call +1 (858) 779-1554. Stay tuned for updates on this developing story.